Moreover, during the evaluation of vemurafenib in a phase II clinical trial, involving NSCLC patients with both BRAFV600 and non-V600 mutations, no objective responses were observed in the non-V600 cohort, indicating a lack of vemurafenib activity in tumors expressing these BRAF alterations. Here, BRAF is linked to non-small cell lung carcinoma.